NCT01110941已完成1 期
A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer
Shen Lin1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2009年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
研究概览
简要总结
S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer. This study is to explore the feasibility of the SOL regimen on efficacy and tolerability on Chinese colorectal cancer patients.
详细描述
-
Endpoints:
-
Primary endpoints: adverse drug reaction
-
Secondary endpoints:
-
Overall Response Rate：ORR
-
Progress Free Survival: PFS
-
Time to Treatment Failure：TTF
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Advanced unresectable or recurrent colorectal cancer patients which meet the following criteria:
- •Willing to sign ICF
- •Could orally take investigational product
- •Pathology diagnosis is adenocarcinoma
- •Above 20 years
- •No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)
- •For recurrent cases, if the patient had received adjuvant chemotherapy that didn't include S-1 and L-OHP in 180 days ago, he/she could be enrolled in
- •With target lesions with diameter which is longer than 1cm in spiral CT or MRI examination within 30 days
- •Lab test within 15 days meet following criteria
- •Hemoglobin higher than 9.0g/dL
- •Leukocyte higher than 12,000/mm3
- •Neutrophil higher than 2,000/mm3
- •PLT higher than 10.0 104/mm3
- •Bilirubin lower than 1.5 times of upper limit of normal range
- •AST,ALT,ALP lower than 2.5 times of upper limit of normal range
- •Creatinine lower than upper limit of normal range
- •When patient has liver metastasis or bone metastasis, the value of AST,ALT,ALP could be within 5 times of upper limit of normal range
- •ECOG 0 or 1
- •Expected survival time more than 90 days
排除标准
- •The patient who meet the following criteria should be excluded from this trial
- •Patients who have severe drug allergic history(including: platinum related drugs,5-FU,FT,LV,5-HT3 receptor antagonist)
- •Attended other clinical trial within 4 weeks
- •Received transfusion of blood,related products or G-CSF within 15 days
- •Received surgery within 4 weeks and the effect hadn't vanished
- •Have diarrhea
- •Have complication of active infection(infection caused fever higher than 38℃)
- •Have complication of poor controlled hypercalcemia,hypertension,diabetes
- •Have complication of severe ECG abnormal or other heart disease which will affect clinical treatment(including: cardiac dysfunction,myocardial infarction,angina)
- •Have complication of severe pulmonary disease(including:interstitial pneumonia,pulmonary fibrosis,severe emphysema)
- •Have complication of psychiatric disorder which will affect clinical treatment or have history of CNS disease
- •Have complication of active gastrointestinal bleeding
- •Have pleural effusion,ascites or pericardial effusion that need drainage
- •Have complication of multiple bone metastasis
- •Have severe complication(including:ileus,renal insufficiency,hepatic insufficiency,cerebrovascular disturbance)
- •Have brain metastasis or suspicious brain metastasis
- •Have active multiple primary cancer
- •Female patients who are in pregnancy or lactation and patients who are not willing to take contraception measures
- •Investigator judge not eligible to this trial
研究组 & 干预措施
SOL
Experimental
single arm
干预措施: S-1, leucovorin, oxaliplatin (Drug)
结局指标
主要结局
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
时间窗: from first administration till 28 days after last dosage
次要结局
- Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)(every 6 weeks)
研究者
Shen Lin
pro
Peking University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric CancerGastric CancerNCT01980407Jilin Provincial Tumor Hospital49
Unknown
1 期
SOX as Adjuvant Chemotherapy for Resectable Gastric CancerGastric CancerNCT01542294Chinese Academy of Medical Sciences71
撤回
1 期
SOX-based CRT for Esophageal Cancer.Esophageal CancerNCT03991104Zhejiang Provincial People's Hospital
尚未招募
2 期
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaSintilimabGastric or Gastroesophageal Junction AdenocarcinomaLocally Advanced Solid TumorS-1HER2-positiveImmunotherapyOxaliplatinNCT05218148Aiping Zhou44
已完成
2 期
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric CancerStomach NeoplasmsNCT01531452Chinese Academy of Medical Sciences43